Skip to main content
NSE - SMEListed
Par Drugs and Chemicals Limited Logo

Par Drugs and Chemicals Limited IPO

Par Drugs and Chemicals Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 52.90 (+3.73%)

Having completed its public offering, Par Drugs and Chemicals Limited's is now listed and trading on the NSE exchange as of 16-05-2019. The IPO raised cumulative capital of 16,72,000 Shares, including 16,72,000 Shares in primary capital infusion.

The IPO was conducted with a price range of ₹51 to ₹51 and minimum investment requirement of 2000 shares. subscription activity between 03-05-2019 and 08-05-2019 reflected market assessment of the offering's valuation and prospects.

The allotment process finalized on 13-05-2019 distributed equity ownership to successful bidders. The listing established a transparent market mechanism for share trading, price discovery, and investor participation in the company's future growth.

Par Drugs IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Par Drugs IPO Key Performance Indicator
Company Financials ( in Lakhs )

Par Drugs IPO About Company

Par Drugs and Chemicals Limited, incorporated in 1999 and based in Gujarat, is engaged in the manufacturing and development of active pharmaceutical ingredients (APIs) and fine chemicals for both domestic and international markets. Its APIs are used in tablets, capsules, and other finished dosages, and it also produces various antacid molecules. The company operates two manufacturing facilities in Ankleshwar and Bhavnagar, Gujarat, and offers a portfolio of 6 fine chemicals and 12 API products sold across 17 countries. Key customers include Dabur India Ltd, Meyer Organics Pvt. Ltd, Cadila Healthcare Ltd., Cipla Ltd, and Pfizer Ltd. For fiscal 2018, international sales accounted for 86.88% of total revenue, while domestic sales contributed 13.12%. The company maintains a testing laboratory to ensure quality standards and provides drying operations to convert liquid products into powders for its clients.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Par Drugs IPO Strength Factors

  1. Diversified Product Range: Offers a wide variety of products.
  2. International Presence: Operates in global markets.
  3. Efficient Distribution: Prompt and reliable sales and distribution network.
  4. Proven Track Record: Established history of strong performance.
  5. Strong Chemistry Capabilities: Expertise in chemical processes and development.

Par Drugs IPO Risk Factors

NA


Par Drugs IPO Lead Manager(s)

  • Pantomath Capital Advisor Private Limited

Par Drugs IPO Promoter(s)

  1. Mr. Falgun Vallabhbhai Savani
  2. Mr. Jignesh Vallabhbhai Savani

Par Drugs IPO Company Details

Par Drugs and Chemicals Limited
Phone:
address:

Par Drugs IPO Registrar

Link Intime India Private Limited
Name:
Phone:

Par Drugs IPO FAQs